Overall, these results suggest that ME1 levels do not directly affect the sensitivity of AML cells to T-cells, suggesting that additional factors might play a role in the ME1-associated survival prediction of AML patients subjected to HSCT. This evidence concerns the gene ME1 and acute myeloid leukemia.